Fig. 6From: SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTsForest plots examining the outcome cardiovascular mortality in participants of 11 CVOTs. There is moderate and significant heterogeneity in the analyses (I2 = 45%)Back to article page